Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Core Viewpoint - A class action securities lawsuit has been filed against Merck & Co., Inc. for alleged securities fraud affecting investors between February 3, 2022, and February 3, 2025 [1][2] Summary by Sections Class Action Details - The lawsuit aims to recover losses for Merck investors who were impacted by the alleged fraud during the specified period [1] - The complaint highlights that Merck had projected $11 billion in revenue from Gardasil sales by 2030, supported by optimistic forecasts regarding consumer demand and vaccination efforts in China [2] Recent Developments - On February 4, 2025, Merck announced it would not meet the previously forecasted$11 billion in Gardasil sales by 2030, citing a halt in shipments to China to reduce inventory due to lower-than-expected demand [2] - Following this announcement, Merck's stock price dropped from $99.79 per share on February 3, 2025, to$90.74 per share on February 4, 2025, marking a decline of over 9% in one day [2] Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]